Smoking Increases Risk of Side Effects, Recurrence in Prostate Cancer
the Cancer Therapy Advisor take:
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer, according to a study published in BJU International.
Michael Zelefsky, MD, and colleagues at the Memorial Sloan Kettering Cancer Center in New York City examined 2,358 patients with prostate cancer who underwent external-beam radiotherapy (EBRT) between 1988 and 2005. They classified patients as never smokers, current smokers, former smokers, or current smoking unknown.
They found that with a median follow-up of about 8 years, current smokers were at a 40 percent increased risk of prostate cancer relapse, along with a two-times increased risk of cancer spread and cancer-related death, compared to never smokers.
Additionally, current and former smokers had a higher likelihood of experiencing side effects such as urinary toxicity that are related to radiotherapy.
“Our findings point to the importance of physicians counseling their patients regarding the potential harms of smoking interfering with the efficacy of therapies ad for increased risks of side effects,” Dr. Zelefsky noted.
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer